Browse Studies — Arctuva

Phase 4

Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression

Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, …

Depression - Major Depressive DisorderTreatment-resistant Depression (TRD)rTMS+2 more

Estimated

~$10 – $6,250

Weill Medical College of Cornell UniversityNCT07680140

Phase 2

A Randomized, Double-blind, Placebo-controlled Trial of ALTO-207 in Adults With Treatment-resistant Depression

The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.

Treatment-resistant Depression (TRD)

Estimated

~$10 – $7,500

Alto NeuroscienceNCT07553637

Observational

Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression (COMBAT-SI)

This is a prospective clinical trial to confirm the effectiveness of bilateral accelerated theta burst stimulation (aTBS) on suicidal ideation (SI), while expl…

Suicidal IdeationTreatment-resistant Depression

Estimated

~$10 – $6,250

University of California, San DiegoNCT05377177

Observational

Parsing Mechanistic Relationships Between Circuits and Negative Valence System Behaviors in Treatment-Resistant Depression With Ultrasound Neuromodulation

Approximately one third of individuals with Major Depressive Disorder (MDD) are considered treatment-resistant, subject to severe disability and risk of suicid…

Treatment-Resistant Depression

Estimated

~$10 – $8,750

Laureate Institute for Brain Research, Inc.NCT07166289